IMMUNOTHERAPY

Immunotherapy, 2019年3月19日(二)

08:45

Organiser’s welcome Remarks

Joe Zhou
08:50

Chair’s opening Remarks

Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
David Lane, Chief Scientist, Agency for Science, Technology and Research (A*STAR)
Byung-Geon Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Byung-Geon Rhee, Chief Executive Officer, SCM Lifescience
Panel discussion
09:40

Pharma Trends: Women health as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
Moderator: Reenita Das, Partner, Frost & Sullivan
Evelyn Pang, Head Of Operations, Sanofi Pasteur
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring Pharmaceuticals
10:20

Speed networking & Networking Refreshment

GOING GLOBAL AND KEEPING IT LOCAL

Frank Jiang
Immunotherapy
11:15

Chair's opening remarks

Frank Jiang, Chief Executive Officer, CStone
Aung Myo
Immunotherapy
11:20

What’s next after PD-L1?

Aung Myo, Vice President, Clinical Development, Tessa Therapeutics
Jeonghoon Han
Immunotherapy
11:40

How do domestic companies gain edge in the competitive global immunotherapy landscape?

Jeonghoon Han, Vice President, Chief Development And Technology Officer, Eutilex Ltd
Frank Jiang
Immunotherapy
12:00

The next big trend in Asia immunotherapy landscape: A case study in China

Frank Jiang, Chief Executive Officer, CStone
Antonio Lee
Immunotherapy
12:20

Development of cell therapy product for pediatric orphan disease - challenges and rewards

  • Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)
  • Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what’s next beyond Asia?
Antonio Lee, Chief Executive Officer And Managing Director, MEDIPOST America
12:40

Exhibition Visit & Networking Lunch

IMMUNO-ONCOLOGY (I-O) IN ASIA

Josemund Menezes
Immunotherapy
14:10

Chair’s opening remarks

Josemund Menezes, Medical Affairs Director, Tessa Therapeutics
Stefan Gluck
Immunotherapy
14:20

Big pharma perspectives: Using global pipeline development to serve Asia’s population

Stefan Glück, Vice President Of Global Medical Affairs, Celgene
Mai Jing Liao
Immunotherapy
14:40

Innovative therapeutics in immuno-oncology and inflammatory diseases

Mai Jing Liao, Co-Founder, Vice President For Business Development And Portfolio Management, Harbour Biomed
Vineet Aggarwal
Immunotherapy
15:00

Reserved for Glenmark Pharmaceuticals

Vineet Aggarwal, Deputy General Manager, Medical Services, APAC, Glenmark Pharmaceuticals
Piers Ingram
Immunotherapy
15:20

Immunotherapy in clinical practices: Opportunities and key challenges (Topic to be confirmed)

Piers Ingram, Chief Executive Officer, Hummingbird Bioscience
15:40

Exhibition Visit & Networking Refreshments

CANCER VACCINES

Dwo Yuan Sia
Immunotherapy
16:40

Beyond prevention: Latest cancer vaccine developments in Asia

Dwo Yuan Sia, Chief Technology Officer, BravoVax Co Ltd
Nick Ede
Immunotherapy
17:00

Gastric and breast cancer vaccines: Case study and latest findings

Nick Ede, Chief Technology Officer, Imugene Ltd
Immunotherapy
17:20

Neoantigen cancer vaccine- the new dawn in immuno-oncology

17:40

Networking Cocktail & End of Conference Day 1

last published: 17/Jan/19 09:15

Immunotherapy, 2019年3月20日(三)

08:45

Organiser’s welcome Remarks

08:50

Chairman’s opening Remarks

Nadia Suttikulpanich
09:00

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public Company
Edward Rosen
09:20

The path to personalised medicine: Key developments

Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Edward Rosen, Leader, Glendevon Life Sciences LLC & Executive in Residence, Columbia Technology Ventures
Panel discussion
09:40

Pharma 4:0 Digital disruption: New players, new opportunities

Moderator: Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis
Teck Jack Tan, Chairman And Medical Director, Northeast Medical Group
Matt Cooper, Business Development And Research Director, NIHR Clinical Research Network
Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & Johnson
David Benshoof Klein, Chief Executive Officer, Click Therapeutics
Raghu Bathina, Founder, Future World Studios
10:20

Roundtable discussion

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Pei Yin Tan, Director, Asia Clinical Operations, Medicine Development Center, Eisai Clinical Research Singapore Pte Ltd

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Charles Stacey, President And Chief Executive Officer, Cerecin

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Phusit Prakongsai, Ministry of Public Health Thailand

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Pratapa Satyanarayana, Former Senior Director And Group Country Head, Dr. Reddy?s Laboratories Ltd.

Table 5 Universal healthcare- Is it really costly?

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Philippe Pinton, Regional Head, Specialty Therapy, Takeda

Table 7 Precision to personalised medicine- How do we get there?

Mrunalini Jagtap, Data Management Lead, SICS, A*STAR

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma

Table 10: The Singapore biotech ecosystem - What comes after the Inflexion?

11:00

Exhibition Visit & Networking Refreshments

TARGETTED THERAPIES

Panel discussion
Immunotherapy
11:40

Overview: Targeted therapies in enabling precision medicine

  • Combination studies in Asia-latest updates
  • Deciding between targeted oncology therapies vs I-O, key considerations
  • Key actions transitioning from followers to leaders in targeted therapies
Moderator: Harish Dave, Chief Medical Officer, AUM Biosciences
Vivian Bian, Chief Operating Officer, BeiGene
Marc Voigt, Chief Executive Officer, Immutep Ltd
Gang Qin, Chief Executive Officer, GeneQuantum Healthcare Suzhou
Wenzhi Tian
Immunotherapy
12:20

Development of next generation tumor immunotherapy

Wenzhi Tian, Chief Executive Officer, ImmuneOnco Biopharma
Vivian Bian
Immunotherapy
12:40

Next generation targeted agents and immuno-oncology therapies

Vivian Bian, Chief Operating Officer, BeiGene
13:00

Exhibition Visit & Networking Lunch

COMBINATION AND NOVEL THERAPIES

George Kopsidas
Immunotherapy
14:30

When two readily becomes one: Opportunities in bispecific antibodies

George Kopsidas, Executive Director, Imunexus
Gang Qin
Immunotherapy
14:50

Next generation combination therapies with bioconjugation

Gang Qin, Chief Executive Officer, GeneQuantum Healthcare Suzhou
Immunotherapy
15:10

When east meets west: Combining immunotherapy with traditional Chinese medicine as complementary treatments

IMMUNOTHERAPY BEYOND ONCOLOGY

Victor Li
Immunotherapy
15:30

Beyond T-cell I-O: Antiviral immunotherapy

Victor Li, Chief Executive Officer, Lion TCR
Antonio Bertoletti, Co-Founder, Lion TCR
Marc Voigt
Immunotherapy
15:50

Immunotherapy in treating autoimmune and degenerative diseases

Marc Voigt, Chief Executive Officer, Immutep Ltd
Alexander Kort
Immunotherapy
16:10

Applying precision and immunotherapy to prevent infectious diseases

Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbH
16:30

End of Phar-East 2019

last published: 17/Jan/19 09:15

* 活動內容有可能不事先告知作更動及調整。